EP0935608A4 - Cytotoxische peptide - Google Patents

Cytotoxische peptide

Info

Publication number
EP0935608A4
EP0935608A4 EP97941730A EP97941730A EP0935608A4 EP 0935608 A4 EP0935608 A4 EP 0935608A4 EP 97941730 A EP97941730 A EP 97941730A EP 97941730 A EP97941730 A EP 97941730A EP 0935608 A4 EP0935608 A4 EP 0935608A4
Authority
EP
European Patent Office
Prior art keywords
cytotoxic peptides
cytotoxic
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97941730A
Other languages
English (en)
French (fr)
Other versions
EP0935608A1 (de
Inventor
Ahmed Azad
Melinda Lowe
Cyril Curtain
Jonathan Baell
Barry Matthews
Ian Macreadie
Chinniah Arunagiri
Don Rivett
Raymond Norton
Kevin Barnham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomolecular Research Institute Ltd
Original Assignee
Biomolecular Research Institute Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPO2659A external-priority patent/AUPO265996A0/en
Priority claimed from AUPO2680A external-priority patent/AUPO268096A0/en
Application filed by Biomolecular Research Institute Ltd filed Critical Biomolecular Research Institute Ltd
Publication of EP0935608A1 publication Critical patent/EP0935608A1/de
Publication of EP0935608A4 publication Critical patent/EP0935608A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/163—Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • AIDS & HIV (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP97941730A 1996-09-27 1997-09-26 Cytotoxische peptide Withdrawn EP0935608A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPO2659A AUPO265996A0 (en) 1996-09-27 1996-09-27 Cytotoxic peptides
AUPO265996 1996-09-27
AUPO2680A AUPO268096A0 (en) 1996-09-30 1996-09-30 Cytotoxic peptides
AUPO268096 1996-09-30
PCT/AU1997/000640 WO1998013377A1 (en) 1996-03-06 1997-09-26 Cytotoxic peptides

Publications (2)

Publication Number Publication Date
EP0935608A1 EP0935608A1 (de) 1999-08-18
EP0935608A4 true EP0935608A4 (de) 2004-09-15

Family

ID=25645279

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97941730A Withdrawn EP0935608A4 (de) 1996-09-27 1997-09-26 Cytotoxische peptide

Country Status (5)

Country Link
EP (1) EP0935608A4 (de)
JP (1) JP2001502897A (de)
AU (1) AU716098B2 (de)
CA (1) CA2263134A1 (de)
WO (1) WO1998013377A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034135A (en) * 1997-03-06 2000-03-07 Promega Biosciences, Inc. Dimeric cationic lipids
DE19820224A1 (de) * 1998-05-06 1999-12-09 Markus Schott Bindungspartner und Verfahren zur kompetitiven Hemmung der Bindung zwischen NEF-Protein und Calmodulin, sowie Mittel und Verwendung bei HIV-Erkrankungen
JP2000000097A (ja) 1998-06-15 2000-01-07 Nippon Zoki Pharmaceut Co Ltd Ｎｅｆ結合蛋白質、該蛋白質をコードするＤＮＡ並びに該蛋白質に対するモノクローナル抗体
CN1312080A (zh) 2000-02-18 2001-09-12 日本脏器制药株式会社 含有脂肪酸的组合物
US20060134646A1 (en) 2004-12-17 2006-06-22 Ansari Aftab A Method for treatment of HIV infection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026776A1 (en) * 1993-05-18 1994-11-24 Biomolecular Research Institute Ltd. Therapeutic compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2090860C (en) * 1990-11-21 2003-09-16 Richard A. Houghten Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026776A1 (en) * 1993-05-18 1994-11-24 Biomolecular Research Institute Ltd. Therapeutic compounds

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CURTAIN C C ET AL: "FUSOGENIC ACTIVITY OF AMINO-TERMINAL REGION OF HIV TYPE 1 NEF PROTEIN", AIDS RESEARCH AND HUMAN RETROVIRUSES, NEW YORK, NY, US, vol. 10, no. 10, October 1994 (1994-10-01), pages 1231 - 1240, XP009005690, ISSN: 0889-2229 *
CURTAIN CYRIL C ET AL: "Cytotoxic activity of the amino-terminal region of HIV type 1 Nef protein", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 13, no. 14, 20 September 1997 (1997-09-20), pages 1213 - 1220, XP008029579, ISSN: 0889-2229 *
CURTAIN CYRIL C ET AL: "Structural requirements for the cytotoxicity of the N-terminal region of HIV type 1 Nef", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 14, no. 17, 20 November 1998 (1998-11-20), pages 1543 - 1551, XP008029578, ISSN: 0889-2229 *
See also references of WO9813377A1 *

Also Published As

Publication number Publication date
JP2001502897A (ja) 2001-03-06
AU716098B2 (en) 2000-02-17
AU4370897A (en) 1998-04-17
CA2263134A1 (en) 1998-04-02
WO1998013377A1 (en) 1998-04-02
EP0935608A1 (de) 1999-08-18

Similar Documents

Publication Publication Date Title
EP0941120A4 (de) Verzweigte peptidlinker
HRP970308B1 (en) Peptide derivatives
EP0765165A4 (de) Peptide mit definierter struktur
HRP970099B1 (en) Peptide derivatives
PL318017A1 (en) Peptides
GB9718110D0 (en) Peptides
EP0746565A4 (de) Mit bombesin verwandte peptide
GB9624562D0 (en) Peptide derivatives
GB9700154D0 (en) Peptides
GB9425380D0 (en) Peptides
EP0935608A4 (de) Cytotoxische peptide
EP0996457A4 (de) Fsh freisetzende peptide
GB9519511D0 (en) Peptides
AUPO324096A0 (en) Linker peptide
GB9613705D0 (en) Novel peptides
GB9425381D0 (en) Peptides
ZA978657B (en) Cytotoxic peptides.
AUPO268096A0 (en) Cytotoxic peptides
GB9612648D0 (en) Peptides
SG55039A1 (en) Peptides
GB9605904D0 (en) Peptides
GB9625227D0 (en) Peptides
GB9626362D0 (en) Peptides
GB9608430D0 (en) Peptides
GB9606765D0 (en) Peptides

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990330

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 38/00 B

Ipc: 7G 01N 33/50 B

Ipc: 7C 07K 7/06 B

Ipc: 7C 07K 14/16 A

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

A4 Supplementary search report drawn up and despatched

Effective date: 20040727

18D Application deemed to be withdrawn

Effective date: 20040401